Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma	IDH1-mutant Glioma; IDH2-mutant Glioma	Active, not recruiting	Phase 1 / Phase 2	2026-07-08		NCT06478212

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Institut de Recherches Internationales Servier	18

28 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Tiantan Hospital, Capital Medical University	Beijing	China	3
Christie Hospital	Manchester	United Kingdom	12
Dana Farber Cancer Institute	Boston	United States	300
Duke University Medical Center	Durham	United States	505
Erasmus MC	Rotterdam	Netherlands	1
H. Valle de Hebron	Barcelona	Spain	1
Hospital 12 de Octubre	Madrid	Spain	14
Huashan Hospital, Fudan University	Shanghai	China	28
Hôpital Pierre Wertheimer	Lyon	France	1
Hôpital Pitié-Salpêtrière	Paris	France	16
Instituto Clinico Humanitas IRCCS	Rozzano	Italy	1
IOV - Ospedale Busonera	Padua	Italy	1
IUCT-Oncopole Institut Universitaire du Cancer	Toulouse	France	2
Kumamoto University Hospital	Kumamoto	Japan	45
Kyoto University Hospital	Kyoto	Japan	56
MD Anderson Cancer Center	Houston	United States	589
Medical University of Vienna - AKH	Vienna	Austria	1
Medizinische Fakultät Mannheim, Universität Heidelberg	Mannheim	Germany	1
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Nagoya University Hospital	Nagoya	Japan	1
National Cancer Center Hospital	Tokyo	Japan	42
Ospedale Molinette - Centro Oncologico Ematologico	Turin	Italy	1
The Royal Marsden in Sutton	Sutton	United Kingdom	1
The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital)	Tel Aviv	Israel	1
University of California Los Angeles	Los Angeles	United States	87

Clinical trials